← All trials
NCT05566054
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2022
- Primary completion
- Sep 30, 2024
- Completion date
- Sep 30, 2025
- First posted
- Oct 4, 2022
- Last posted
- Oct 5, 2022
- Enrollment
- 92
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Soochow UniversityLead sponsor
- Nantong UniversityCollaborator
- Bengbu Medical CollegeCollaborator
- Nanjing Medical UniversityCollaborator
- Nanjing Medical UniversityCollaborator
- Suzhou Hospital of Traditional Chinese MedicineCollaborator
- Soochow UniversityReponsible party - principal investigator
- The Second People's Hospital of Huai'anCollaborator
- Soochow UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.